Result
€541,117 €541,117
Back in profit in 2025, after a loss of €92,638 in 2024.
Pharma2Care
Lifetime
17 annual accounts with figures on one time axis, 41 filings since 1985peak €1.3m (2020)
€795,580▲ €805,358
lowest -€402,142 (2014)
€541,117▲ €633,754
peak €1.6m (2025)
€1.6m▲ 52.0%
€6,879▼ 99.3%
peak 14.4 FTE (2013)
-not published
Board2 names since 2018
1 directorPharma Force NV
Owners2 names in the annual accounts
consolidatespeeters mathieu management
Documentsfilings and deeds
23-10-202684 days late
2025financial year
Gross margin from -€9,779 to €795,580Back to profit: €541,117Equity from €1.0m to €1.6mDebts from €971,563 to €6,879Cash from €1,168 to €335
Key points
from the 2025 annual accountsFilings
41 annual accounts 84 days
Latest accounts filed late: after the legal deadline.
Position in the sector
88.4%
Higher solvency than 94% of companies in retail trade. Sector median 36.2% · 5,061 companies.
Checked score
72
Healthy
Financially stronger than 82% of micro companies in retail trade (NACE 47)
Probability in this band: 0.55% to 1.5%
Bankruptcy probability within 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,280 companies (NACE 47, micro).
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.3%
01-2025: 0.3%● unchanged vs 12-2024
02-2025: 0.3%● unchanged vs 01-2025
03-2025: 0.3%● unchanged vs 02-2025
04-2025: 0.3%● unchanged vs 03-2025
05-2025: 0.3%● unchanged vs 04-2025
06-2025: 0.2%▼ -0.1 percentage points vs 05-2025lowest value
07-2025: 0.3%▲ +0.1 percentage points vs 06-2025
08-2025: 0.3%● unchanged vs 07-2025
09-2025: 0.3%● unchanged vs 08-2025
10-2025: 0.3%● unchanged vs 09-2025
11-2025: 0.3%● unchanged vs 10-2025
12-2025: 0.3%● unchanged vs 11-2025
01-2026: 0.3%● unchanged vs 12-2025
02-2026: 0.3%● unchanged vs 01-2026
03-2026: 0.3%● unchanged vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.4%▲ +0.1 percentage points vs 04-2026
06-2026: 0.4%● unchanged vs 05-2026
07-2026: 0.4%● unchanged vs 06-2026
08-2026: 0.7%▲ +0.3 percentage points vs 07-2026
09-2026: 0.9%▲ +0.2 percentage points vs 08-2026highest value
10-2026: 0.6%▼ -0.3 percentage points vs 09-2026
11-2026: 0.6%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Liquidity: current ratio 260.10, cash €335, halved
Last filed accounts filed 84 days late; 1 of the last 3 accounts late
Sector: Retail trade (NACE 47)
lowers risk
Founded in 1985
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 92% of them on solvency, 54% on liquidity, 96% on profitability and 86% on growth.
The bankruptcy probability was computed on 06-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 20,137 companies had the same profile as Pharma2Care has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
The bankruptcy probability of Pharma2Care itself is higher: 0.6% within 12 months. It rests on far more data about Pharma2Care than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,137 companies, not a prediction for Pharma2Care. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €110,000 on 30-day terms is acceptable
Short-term debt is 0.4% and cash 0% of total assets. 11.6% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · A punctual record breaks
This company filed 8 consecutive financial years on time. The year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 23-10-2026, 84 days late. Weigh it accordingly: of the companies that move to filing 1 to 90 days late, 1.41% are now bankrupt, dissolved or in another special legal status, below the 1.66% of all filers. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filingsDeviation from the deadline
2025
84 days late
2024
38 days early
2023
on the day
2022
20 days early
2021
37 days early
2020
1 day early
2019
11 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 3 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 11 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
07-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
PF
Pharma Force NV
Director, since 13-07-2018
- peeters mathieu management 100%score 51equity €8.7m (2024) · 2024 annual accounts of peeters mathieu management
- Peeters Mathieu Management BV consolidatesannual accounts 2025
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0427391896
Permanent representative: MATHIEU PEETERS
General meeting of 06-12-2022 · Gazette deed
First establishment
Nieuwe Steenweg 50, Zuienkerke
Incorporation
published on 18-06-1985 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Pharma2Care Zuienkerke | €1.8m | €795,580 | 88.4% | - |
| APOTHEEK ORBIE Middelkerke | €1.8m | €869,320 | 68.0% | 5 |
| LA PHARMACIE DE VRIESE Nivelles | €1.8m | €831,424 | 17.4% | 5.7 |
| Pharmacie Bastin Médiacité Liège | €1.8m | €799,524 | 13.7% | 9.1 |
| Pharmacie RONDELET Ouffet | €1.8m | €787,738 | 28.7% | 5.3 |
| Apotheek Matton Brussels | €1.9m | €713,574 | 65.4% | 5.6 |
| GOESSAERT Zulte | €2.0m | €814,793 | 37.6% | 4.7 |
These companies have the same main activity as Pharma2Care: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.8m and €2m, founded between 1981 and 1987.
Official details
Source: KBO- Status
- Active since 29-05-1985Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 1 other
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2023
- Establishment unit
- 2.030.254.8378377 Zuienkerke, since 02-07-1985
- Financial year end
- 31 December
- Peppol
- Reachable since 17-07-2025
Insights on Pharma2Care
Pharma2Care has existed since 1985. The gross margin fell from €471,061 in 2006 to €3,035 in 2007 and staff from 9.2 to 1.5 full-time equivalents.
Solvency rose in 2025 from 51.7% to 88.4% because of the retained profit and lower debts.
peeters mathieu management holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Pharma2Care
- What is the company number of Pharma2Care?
- The company number of Pharma2Care is 0427.391.896. The VAT number is the same number with BE in front: BE 0427.391.896.
- Where is Pharma2Care based?
- The registered office is at Nieuwe Steenweg 50, 8377 Zuienkerke.Company details
- What does Pharma2Care do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Pharma2Care?
- Pharma2Care is a public limited company (NV).
- When was Pharma2Care founded?
- Pharma2Care was founded on 29-05-1985.
- Is Pharma2Care still active?
- Yes, Pharma2Care is an active enterprise in the KBO register.
- How many employees does Pharma2Care have?
- Pharma2Care had an average of 3.1 full-time equivalents in financial year 2023, according to the filed annual accounts.Financials
- Which joint committee does Pharma2Care fall under?
- In its 2023 annual accounts, Pharma2Care states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of Pharma2Care?
- The turnover in financial year 2025 is ≈ €2.8m. This figure is estimated from the gross margin of €795,580 and 47 comparable companies (NACE 477). It probably lies between €2.2m and €4.5m.
- Is Pharma2Care profitable?
- In financial year 2025, Pharma2Care made a profit of €541,117.
- Where can I find the annual accounts of Pharma2Care?
- Pharma2Care filed 41 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Pharma2Care due?
- Pharma2Care must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See the other companies in the same group.peeters mathieu management · 9 companies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.